<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190202</url>
  </required_header>
  <id_info>
    <org_study_id>114001</org_study_id>
    <nct_id>NCT01190202</nct_id>
  </id_info>
  <brief_title>Epidemiology Study of Malaria Transmission Intensity in Africa</brief_title>
  <official_title>Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The PATH Malaria Vaccine Initiative (MVI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The aim of this epidemiology study is to characterize in a standardized way malaria
      transmission intensity at the clinical trial centers participating in study 110021
      (NCT00866619).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter epidemiology study at centers that are participating in GSK's
      pivotal Phase III candidate malaria vaccine 110021 ( NCT00866619) trial and will involve 4
      annual cross sectional surveys performed preferably at peak transmission.

      There will be no study vaccine administered in this epidemiology study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Plasmodium falciparum parasitemia during the first year</measure>
    <time_frame>At year 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of P. falciparum parasitemia during the second year</measure>
    <time_frame>At year 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of P. falciparum parasitemia during the third year</measure>
    <time_frame>At year 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of P. falciparum parasitemia during the fourth year</measure>
    <time_frame>At year 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of P. falciparum parasitemia</measure>
    <time_frame>At years 1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anemia</measure>
    <time_frame>At years 1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-malarial therapy</measure>
    <time_frame>At years 1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of fever</measure>
    <time_frame>At years 1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of each risk factor</measure>
    <time_frame>At years 1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of malaria prevention measures</measure>
    <time_frame>At years 1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of other Plasmodium parasitemia</measure>
    <time_frame>At years 1, 2, 3 and 4</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">13380</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Subjects</arm_group_label>
    <description>Subjects at least 6 months of age, enrolled in catchment areas of study 110021 (NCT00866619).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Capillary blood samples collected by finger/heel prick</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Assessment of body temperature</intervention_name>
    <description>Assessment of axial body temperature with a digital thermometer</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects at least 6 months of age will be enrolled in catchment areas of a Phase III trial
        of the candidate malaria vaccine in sub-Saharan Africa (study 110021 (NCT00866619));
        participants of study 110021 are excluded from this epidemiology study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parent(s)/Legally
             Acceptable Representative(s) can and will comply with the requirements of the
             protocol.

          -  A male or female 6 months or older at the time of survey.

          -  Written informed consent obtained from the subject/from the parent(s)/ Legally
             Acceptable Representative(s) of the subject.

        Exclusion Criteria:

          -  Child in care.

          -  Previous or current participation in any malaria vaccine trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ouagadougou 01</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lambaréné</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kintampo</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kumasi</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dar-es-Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Korogwe, Tanga</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Gabon</country>
    <country>Ghana</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 29, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

